eht


Also found in: Acronyms, Wikipedia.

eht

(electromagnetism)
Mentioned in ?
References in periodicals archive ?
pt] is the share of EHT spending in total expenditure.
The EHT concept today is the result of a significant evolution.
EHT 0201 was selected from a library of compounds for clinical development, following an evaluation of its pharmacological effects (including comparisons with riluzole) against a subset of these new molecular targets.
Assuming successful clinical validation, ExonHit Therapeutics plans to launch EHT Dx21 as a Research Use Only product in the clinical trial market in Q4 2009, and in the clinical diagnostic market in a second step through a partnering model.
The publication of these promising first patient data in a peer-reviewed Alzheimer's disease journal highlights the interest of the Alzheimer's scientific community in our EHT 0202 compound.
The successful completion of patient enrolment for the Phase IIa represents an important milestone in the development of EHT 0202, and provides a clear timeline for the release of results," stated Dr.
EHT Dx14 was able during the initial study to differentiate benign breast tumors from malignant ones in 96% of the cases (1).
Introduction of EHT Dx14 as an Investigational Use Only product
The Phase 1, randomized, double-blind, placebo-controlled, crossover study with 3 treatments and the placebo being administered over 4 distinct periods in 12 young healthy subjects assessed the effects of single administrations of EHT 0202 (40mg, 80mg, and 120mg) on scopolamine-induced (0.
Awards allocated to AclarusDx[TM] in Alzheimer's disease and the EHT 107 program in oncology
PARIS, December 20 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease.
This is what we have done with EHT 0202, our Phase II compound in Alzheimer's disease," added Matthew Pando, PhD, Executive Vice President, Therapeutics of ExonHit Therapeutics.